Drug intelligence / Profile preview

PZ01 CAR-T

Development stage: Phase 1
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Vaccines & Immunotherapeutics
Administration: Intravenous

Overview

PZ01 CAR-T is a chimeric antigen receptor (CAR) T cell therapy developed for the treatment of B-cell lymphomas. CAR-T therapies are autologous cell therapies in which a patient's own T cells are genetically engineered ex vivo to express a synthetic receptor (CAR) that targets specific antigens on cancer cells; in this case, PZ01 CAR-T cells are designed to target B-cell lymphoma antigens. Upon infusion, these modified T cells recognize and kill malignant B lymphocytes through direct cytotoxic effects. PZ01 CAR-T is currently in Phase 1 clinical trials for B-cell lymphoma[1].

Brand names: PZ01 CAR-TPZ-01 CAR-TPZ 01 CAR-T
Other names: PZ01 CAR-TPZ-01 CAR-TPZ 01 CAR-T

Targets

CD19 (B lymphocyte antigen CD19)CD20 (B-lymphocyte antigen CD20)

Beyond the preview

Go deeper on PZ01 CAR-T.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PZ01 CAR-T.

Explore the full profile